Vivos Therapeutics Inc.
VVOS | NASDAQ
$0.50
-$0.01 (-2.19%)
Jun 18, 2026, 4:00 PM ET · Market open
Company Profile
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
Key Executives
| Name | Position |
|---|---|
| Jennifer Hauser | Executive Assistant to CEO and Chairman & CFO |
| R. Kirk Huntsman | Co-Founder, Chairman of the Board & Chief Executive Officer |
| Bradford K. Amman | Chief Financial Officer, Treasurer & Secretary |
| John Ballard | Senior Vice President of Technology |
| Michael E. Bruhn | Executive Vice President of Business Operations Integration |
| Nicholas DeGennaro | Senior Vice President of Mergers and Acquisition Group |
| RaeAnn Byrnes | Co-Founder and Senior Vice President of Events & Clinical Advisory Services |
| Ruth Hembree | Senior Vice President of Practice Services |
| Susan McCullough | Co-Founder & Executive Vice President of Operations |
| Terry Jones | Senior Vice President of Human Resources |
| Todd Huntsman | Co-Founder & Senior Vice President of Product and Technology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 20, 2026 | 10-Q | Quarterly Report |
| May 15, 2026 | NT 10-Q | Filing |
| May 15, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| May 08, 2026 | EFFECT | Filing |
| May 08, 2026 | 424B3 | Filing |
| Apr 30, 2026 | S-3/A | [Amend] Filing |
| Apr 22, 2026 | 8-K | Current Report |
| Apr 15, 2026 | 8-K | Current Report |
| Apr 15, 2026 | 10-K | Annual Report |
| Apr 10, 2026 | 3 | Filing |
Vivos Therapeutics Inc.
| Country | United States |
| IPO Date | Dec 10, 2020 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 109 |
| CEO | R. Kirk Huntsman |
Contact Details
9137 Ridgeline Boulevard Highlands Ranch,
Colorado 80129 United States
Stock Details
| Ticker Symbol | VVOS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001716166 |
| CUSIP Number | 92859E108 |
| ISIN Number | US92859E2072 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove VVOS